UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K...
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:March 09, 2022...
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 1, 2022...
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 6-KReport of Foreign Private...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM&n...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under...
SCHEDULE 13G Amendment No. 0 PROQR THERAPEUTICS NV COMMON STOCK Cusip #N71542109 Check the appropriate box to...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange...
UNITED STATES SECURITIES AND EXCHANGE...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...
In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on ProQR (PRQR β Research Report), with a price target...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads